Immunomodulation during sepsis in organ transplanted children

Minerva Pediatrica

Volumn 57, Issue 5, 2005, Pages 259-268

  Angele, M K ^a   Loehe, F ^a   Faist, E ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Child; Immunomodulators; Organ transplantation; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ARGININE; CD14 ANTIGEN; CYCLOSPORIN; CYTOKINE; FISH OIL; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; LIPOPOLYSACCHARIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

APOPTOSIS; CELLULAR IMMUNITY; DIET; GRANULOCYTE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MORTALITY; NEOPLASM; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGE FACTORS; ANIMALS; ARGININE; CHILD; CYTOKINES; DATA INTERPRETATION, STATISTICAL; DISEASE MODELS, ANIMAL; FEMALE; FISH OILS; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; MALE; ORGAN TRANSPLANTATION; PLATELET MEMBRANE GLYCOPROTEINS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, G-PROTEIN-COUPLED; SEPSIS;

EID: 28244447395     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Vilca-Melendez H, Heaton ND. Paediatric liver transplantation: the surgical view. Postgrad Med J 2004;80:571-6.
2. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004;4:384-9.
3. Trzeciak S, Sharer R, Piper D, Chan T, Kessler C, Dellinger RP et al. Infections and severe sepsis in solid-organ transplant patients admitted from a university-based ED. Am J Emerg Med 2004;22:530-3.
4. Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents: efficacy, side effects, and utilization. Pediatr Clin North Am 2003;50:1283-300.
5. Angele MK, Faist E. Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. Grit Care 2002;6:298-305.
6. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
7. Ertel W, Morrison MH, Wang P, Ba ZF, Ayala A, Chaudry IH. The complex pattern of cytokines in sepsis - Association between prostaglandins, cachectin and interleukins. Ann Surg 1991;214:141-8.
8. Faist E, Meakins J, Schildberg FW. Host Defense Dysfunction in Trauma, Shock and Sepsis. Berlin-Heidelberg: Springer-Verlag; 1993.
9. Schinkel C, Sendtner R, Zimmer S, Faist E. Functional analysis of monocyte subsets in surgical sepsis. J Trauma 1998;44:743-8.
10. Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH. Polymicrobial sepsis but not low dose endotoxin infusion causes decreased splenocyte IL-2/IFN-gamma release while increasing IL-4/IL-10 production. J Surg Res 1994;56:579-85.
11. Weimer R, Melk A, Daniel V, Friemann S, Padberg W, Opelz G. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2, and monokine responses. Hum Immunol 2000;61:884-97.
12. Steininger C, Kundi M, Kletzmayr J, Aberle SW, Popow-Kraupp T. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 2004;190:1908-12.
13. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Predicting bacteremia and bacteremic mortality in liver transplant recipients. Liver Transpl 2000;6:54-61.
14. Esmon CT. The normal role of activated protein C in maintaining homeostasis and its relevance to critical illness. Crit Care 2001;5:S7-12.
15. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004;104:3878-85.
16. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
17. Fry DE, Beilman G1 Johnson S, Williams MD, Rodman G, Booth FV et al. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis. Surg Infect (Larchmt.) 2004;5:253-9.
18. Kulkarni S, Naureckas E, Cronin DC. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplantation 2003;75:899-901.
19. Luiking YC, Poeze M, Dejong CH, Ramsay G, Deutz NE. Sepsis: an arginine deficiency state? Crit Care Med 2004;32:2135-45.
20. Zhou M, Wang P, Chaudry IH. Endothelial nitric oxide synthase is downregulated during hyperdynamic sepsis. Biochim Biophys Acta 1997;1335:182-90.
21. Angele MK, Smail N, Knoferl MW, Ayala A, Cioffi WG, Chaudry IH. L-arginine restores splenocyte functions after trauma-hemorrhage potentially by improving splenic blood flow. Am J Physiol 1999;276:C145-51.
22. Angele MK, Smail N, Wang P, Cioffi WG, Bland KI, Chaudry IH. L-Arginine restores the depressed cardiac output and regional perfusion following trauma-hemorrhage. Surgery 1998;124:394-401.
23. Luiking YC, Poeze M, Ramsay G, Deutz NE. The role of arginine in infection and sepsis. JPEN J Parenter Enterai Nutr 2005;29:S70-4.
24. Plank LD, McCall JL, Gane EJ, Rafique M, Gillanders LK, McIlroy K et al. Pre- and postoperative immunonutrition in patients undergoing liver transplantation: a pilot study of safety and efficacy. Clin Nutr 2005:24:288-96.
25. Wesley AJ, Metze TJ, McIntosh MJ, Goodman HR, First MR, Munda R et al. The influence of immunomodulatory diets on transplant success and complications. Clin Transpl 2005;79:460-5.
26. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30.
27. Stechmiller JK, Childress B, Porter T. Arginine immunonutrition in critically ill patients: a clinical dilemma. Am J Crit Care 2004;13:17-23.
28. Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001;286:944-53.
29. Ertel W, Morrison MH, Ayala A, Chaudry IH. Biological significance of elevated TNF levels: in vivo administration of monoclonal antibody against TNF following haemorrhagic shock increases the capacity of macrophages to release TNF while restoring immunoresponsiveness. Cytokine 1994;6:624-32.
30. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697-702.
31. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004;32:2173-82.
32. Remick DG, Call DR, Ebong SJ, Newcomb DE, Nybom P, Nemzek JA et al. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit Care Med 2001;29:473-81.
33. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3;678-81.
34. Anderson BO, Bensard DD, Harken AH. The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstet 1991;172:4l5-24.
35. Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004:32:332-41.
36. Suputtamongkol Y, Intaranongpai S, Smith MD, Angus B, Chaowagul W, Permpikul C et al. A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother 2000;44:693-6.
37. Ziegler-Heitbrock HW, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunology Today 1993:14:121-5.
38. Dziarski R, Tapping RI, Tobias PS. Binding of bacterial peptidoglycan to CD14. J Biol Chem 1998;273:8680-90
39. Ulevitch RJ. Endotoxin opens the Tollgates to innate immunity. Nat Med 1999;5:144-5.
40. Wright SD. CD14 and innate recognition of bacteria. J Immunol 1995:155:6-8.
41. Marsh CB, Wewers MD. The pathogenesis of sepsis. Factors that modulate the response to gram-negative bacterial infection. Clin Chest Med 1996;17:183-97.
42. Schimke J, Mathison J, Morgiewicz J, Ulevitch RJ. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA 1998;95:13875-80.
43. Leturcq DJ, Moriarty AM, Talbott G, Winn RK, Martin TR, Ulevitch RJ. Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest 1996;98:1533-8.
44. Verbon A, Meijers JC, Spek CA, Hack CE, Pribble JP, Turner T et al. Effects of IC14, an anti-CDl4 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. J Infect Dis 2003;187:55-61.
45. Reinhart K, Gluck T, Ligtenberg J, Tschaikowsky K, Bruining A, Bakker J et al. CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med 2004;32:1100-8.
46. Schneider C, von Aulock S, Zedler S, Schinkel C, Hartung T, Faist E. Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 2004;239:75-81.
47. Foster PF, Mital D, Sankary HN, McChesney LP, Marcon J, Koukoulis G et al. The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation 1995;59:1557-63.
48. Winston DJ, Foster PF, Somberg KA, Busuttil RW, Levy MF, Sheiner PA et al. Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation 1999;68:1298-304.
49. Schmaldienst S, Bekesi G, Deicher R, Franz M, Horl WH, Pohanka E. Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation. Transplantation 2000;69:527-31.
50. Freeman BD, Quezado Z, Zeni F, Natanson C, Danner RL, Banks S et al. rG-CSF reduces endotoxemia and improves survival during E. coli pneumonia. J Appl Physiol 1997;83:1467-75.
51. Quezado Z, Parent C, Karzai W, Depietro M, Natansoh C, Hammond W et al. Acute G-CSF therapy is not protective during lethal E. coli sepsis. Am J Physiol Regul Integr Comp Physiol 2001;281:R1177-85.